Vishwesha Theertha Swami, Seer of Udupi Pejawar Mutt, Passes Away at 88

Mar 5: The government on Thursday asserted that there is no shortage of raw ingredients or medicines in the country as it has taken various initiatives to tackle the challenge posed by the coronavirus outbreak.

All initiatives are also being taken to ensure that there is no impact of the disease in India, Minister of Chemicals and Fertilizers D V Sadananda Gowda said.

"There is no shortage of any APIs in the country. We have sufficient APIs (active pharmaceutical ingredients) and medicines in the country," he said.

Gowda was addressing the 5th international exhibition and conference on the pharmaceutical and medical industry organised by the Department of Pharmaceuticals, Gujarat government and industry chamber Ficci here.

For another three months there is no shortage for undertaking production in the pharma sector, he added.

"Our government has taken all initiatives to ensure that as far as our country is concerned the coronavirus should be stopped, and there is no hazard as far as this issue is concerned," Gowda reiterated.

Coronavirus is a challenge and "we should make all efforts that need to be taken..., " he added.

On Tuesday, India, the world's largest maker of generic drugs, restricted the export of common medicines such as paracetamol and 25 other pharmaceutical ingredients and drugs made from them, as it looks to prevent shortages amid concerns of the coronavirus outbreak turning into a pandemic.

Besides over-the-counter painkiller and fever reducer paracetamol, drugs restricted for exports included common antibiotics metronidazole, and those used to treat bacterial and other infections as well as Vitamin B1 and B12 ingredients.

A notification by the Directorate General of Foreign Trade (DGFT) had said the export of 26 active pharmaceutical ingredients (APIs) and formulations would require licence.

Bengaluru, Mar 25 : Karnataka recorded its highest single-day tally to date, as 10 people tested positive, taking the total number of cases to 51 in the state.

“Till date 51 COVID-19 positive cases have been confirmed in the state which includes one death and three discharged," the health department said in a statement on Wednesday.

The rise in cases adding to the growing national tally of people who have tested positive for COVID-19.

The daughter of a former union minister from the Bharatiya Janata Party (BJP) from Karnataka has also tested positive.

Bengaluru accounts for 32 of the total 51 cases recorded in the state so far,including three who have fully recovered and released.

Dakshina Kannada has five confirmed cases, Chikkaballapura and Kalaburagi has three cases each, Mysuru has and Uttara Kannada has two cases each and four other districts have one case each.

Prime Minister Narendra Modi has announced a 21-day lockdown of the country to keep people indoors and contain the spread of the virus in the community.

The government has also been trying to scale up testing.

Medical education minister K.Sudhakar on Wednesday told Mint that Karnataka will scale up testing by 10-fold with the help of government and private labs approved by the Indian Council of Medical Research (ICMR).

A total of 2,438 people have been tested in Karnataka and 2242 have tested negative, according to state health department. 214 people are lodged in medical hospitals.

Bengaluru, Jul 26: Today, one of the Co-founders of Infosys, SD Shibulal announced that over the last three days (22nd - 24th July) his family members have sold a portion of (representing approximately 0.20 per cent of the paid-up equity share capital) their holding in Infosys Ltd on the stock exchanges.

Proceeds from the partial stake monetization will be utilized for a combination of philanthropic and investment activities.

The sale was executed by Citigroup Global Markets India Private Limited as the Sole Broker.

The Founders, have served Infosys in various capacities, since its inception in 1981 until October 2014. Over the three decades, the Founders have nurtured the company transforming it into one of the professionally run companies in India with a global presence.

This press release is for information purposes only and is not an offer to sell, or a solicitation of an offer to buy, any of the shares described herein. The shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or in any state or other jurisdiction of the United States.

Securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the US Securities Act. 

There has not been and there will not be any public offering of the shares in the United States.